Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States von Tremblay, Gabriel, Said, Qayyim, Roy, Anuja Nidumolu, Cai, Beilei, Ashton Garib, Shan, Hearnden, Jaclyn, Forsythe, Anna

Volltext

Unresectable hepatocellular carcinoma treated with lenvatinib or sorafenib: A disease modeling study von Tremblay, Gabriel, Copher, Ronda, Garib, Shan Ashton, Pan, Janice

Volltext

Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence von Watson, Crystal, Xu, Hairong, Forsythe, Anna, Garib, Shan Ashton, Barlev, Arie

Volltext

Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Syste... von Xu, Hairong, Watson, Crystal, Garib, Shan Ashton, Forsythe, Anna, Barlev, Arie

Volltext

Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis von Tremblay, Gabriel, Said, Qayyim, Cai, Beilei, Garib, Shan Ashton, Tomaras, Dimitrios, Forsythe, Anna, Roy, Anuja

Volltext

Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia von Tremblay, Gabriel, Chounta, Vasiliki, Piercy, James, Holbrook, Tim, Garib, Shan Ashton, Bukin, Evgeny K., Punekar, Yogesh Suresh

Volltext